respiratory syncytial virus (RSV) vaccine, bivalent (Pending FDA Approval)

Brand and Other Names:
  • Print
Sections

Dosing & Uses

Prevention of Respiratory Syncytial Infection

Pending FDA approval for prevention of respiratory syncytial infection (RSV) in adults aged ≥60 years

Next:

Pharmacology

Mechanism of Action

Bivalent vaccine composed of equal amounts of recombinant RSV prefusion F from subgroups A and B

Crystal structure of prefusion F is a key form of the viral fusion protein (F) that RSV uses to enter human cells; antibodies specific to the prefusion form have shown to be highly effective at blocking virus infection, therefore, a prefusion F-based vaccine may confer optimal protection against RSV

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.